Vivus Inc

VVUS

— Innovative ethanol-free formulation intended to provide improved safety and advance care for patients undergoing high-dose conditioning therapy prior to autologous hematopoietic cell transplantation (AHCT)

— Segment to air on Lifetime on Wednesday, March 19, at 7:30 AM ET/PT CAMPBELL, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced an exclusive episode on Health Uncensored with Dr. Drew.

-  A new path in weight management is now available -  UAE is the first country in the Middle East to have QSYMIA® available -  Rising obesity rates cost UAE nearly $12 billion annually CAMPBELL, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, announced the market approval of QSYMIA® (phentermine and topiramate extended-release capsules) CIV in the United Arab Emirates (UAE) for treatment of overweight and obesity in adults and pediatric patients, age 12 and older.

VIVUS reaffirms commitment to combatting global obesity crisis on World Obesity Day 2025 with VIVUS For Life CAMPBELL, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- VIVUS, LLC.

CAMPBELL, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced it will provide updates to its pipeline and key program milestones during the 43rd Annual J.P. Morgan Healthcare Conference 2025.

- Postmarketing requirement fulfilled based on data demonstrating QYSMIA® reduces blood pressure - CAMPBELL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- VIVUS announced today that the U.S. Food and Drug Administration has removed the requirement for a cardiovascular outcome trial for its weight-management medication QSYMIA (phentermine and topiramate extended release capsules) CIV.